-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NAQZbtrZ7Fb/fAE4fFmfVlXEIbKdzgKNak1fbO04iRytErWj7klVrjjVJxGRkWME
 L8DHZwv2a3uMbIzZMmSt0w==

<SEC-DOCUMENT>0000012208-09-000007.txt : 20090226
<SEC-HEADER>0000012208-09-000007.hdr.sgml : 20090226
<ACCEPTANCE-DATETIME>20090226163253
ACCESSION NUMBER:		0000012208-09-000007
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20081231
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090226
DATE AS OF CHANGE:		20090226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		09638183

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k02262009.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES</TITLE>
<META NAME="author" CONTENT="Tom Brida">
<META NAME="date" CONTENT="02/14/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>UNITED STATES</B></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>CURRENT REPORT</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Date of Report: February 26, 2009</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Date of earliest event reported)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>BIO-RAD LABORATORIES, INC.</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Exact name of registrant as specified in its charter)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=360></TD><TD width=7.133></TD><TD width=352.8></TD></TR>
<TR><TD width=719.933 colspan=3><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Commission File Number: 1-7928</B></P>
</TD></TR>
<TR><TD width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=360><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD width=352.8><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Delaware</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(State or other jurisdiction of</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>incorporation or organization)</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(I.R.S. Employer</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Identification No.)</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=719.933 colspan=3><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>1000 Alfred Nobel Dr.</B></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Hercules, California 94547</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Address of principal executive offices, including zip code)</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=719.933 colspan=3><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>(510) 724-7000</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Registrant&#146;s telephone number, including area code)</B></P>
</TD></TR>
</TABLE>
<P style="line-height:10.667px; margin:0px; font-size:10.667px">&nbsp;</P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=607.2></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=607.2><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=607.2></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=607.2><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=607.2></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=607.2><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=607.2></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=607.2><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><B>&nbsp;</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=96></TD><TD width=540></TD></TR>
<TR><TD valign=top width=96><P style="margin:0px" align=justify><B>ITEM 2.02</B></P>
</TD><TD valign=top width=540><P style="margin:0px"><B>Results of Operations and Financial Condition</B></P>
</TD></TR>
<TR><TD valign=top width=636 colspan=2><P style="margin-top:4.467px; margin-bottom:0px">On February 26, 2009, Bio-Rad Laboratories, Inc. announced its results of operations and financial condition as of and for the year ended December 31, 2008. &nbsp;A copy of the press release is furnished as Exhibit 99.1 to this report.</P>
</TD></TR>
<TR><TD valign=top width=636 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=636 colspan=2><P style="margin:0px">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=80.267></TD><TD width=15.733></TD><TD width=540></TD></TR>
<TR><TD valign=top width=80.267><P style="margin:0px"><B>ITEM 9.01</B></P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="margin:0px"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
<TR><TD valign=top width=80.267><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=80.267><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=80.267><P style="margin:0px"><B>Exhibit</B></P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=top width=80.267><P style="margin:0px"><B>Number</B></P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=540><P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=80.267><P style="margin-top:4.467px; margin-bottom:0px" align=right>99.1&nbsp;</P>
</TD><TD valign=top width=15.733><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=540><P style="margin-top:4.467px; margin-bottom:0px">Press release of Bio-Rad Laboratories, Inc. dated February 26, 2009</P>
</TD></TR>
</TABLE>
<P style="margin-top:4.467px; margin-bottom:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>SIGNATURES</B></P>
<P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=50.867></TD><TD width=136.333></TD><TD width=29.467></TD><TD width=29.467></TD><TD width=4></TD><TD width=253.867></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=287.333 colspan=3><P style="line-height:17.333px; margin:0px; font-size:14.667px">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="line-height:17.333px; margin:0px; font-size:14.667px">Date:</P>
</TD><TD style="border-bottom:1px solid #000000" width=136.333><P style="line-height:17.333px; margin:0px; font-size:14.667px">February 26, 2009</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="line-height:17.333px; margin:0px; font-size:14.667px">By:</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=257.867 colspan=2><P style="line-height:17.333px; margin:0px; font-size:14.667px">/s/ Christine A. Tsingos</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="line-height:17.333px; margin:0px; font-size:14.667px">Christine A. Tsingos<U> </U></P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="line-height:17.333px; margin:0px; font-size:14.667px">Vice President, Chief Financial Officer</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=bottom width=253.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<A NAME="id_11"></A><A NAME="id_12"></A><P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>EXHIBIT INDEX</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=60></TD><TD width=12></TD><TD width=432></TD></TR>
<TR><TD width=60><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=12><P style="margin:0px">&nbsp;</P>
</TD><TD width=432><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=60><P style="line-height:17.333px; margin:0px; font-size:14.667px">Exhibit</P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px">Number</P>
</TD><TD valign=bottom width=12><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=432><P style="line-height:17.333px; margin:0px; font-size:14.667px">Description</P>
</TD></TR>
<TR><TD valign=top width=60><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=right>99.1&nbsp;</P>
</TD><TD valign=bottom width=12><P style="margin:0px; font-size:14.667px">&nbsp;</P>
</TD><TD valign=bottom width=432><P style="line-height:17.333px; margin:0px; font-size:14.667px">Press release of Bio-Rad Laboratories, Inc. dated February 26, 2009</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh99112312008.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="02/25/2009">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:604.8px"><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=right><B><U>Exhibit 99.1</U></B></P>
<P style="margin:0px" align=right><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:14.667px; margin:0px; padding-right:43.2px; font-family:Arial; font-size:12px"><FONT FACE="Arial"><B><I>FOR IMMEDIATE RELEASE</I></B></FONT></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:20px; margin:0px; padding-right:-24px; font-family:HelveticaNeueLT Std; font-size:17.333px" align=center><FONT FACE="HelveticaNeueLT Std"><B>BIO-RAD REPORTS FOURTH-QUARTER AND FULL-YEAR </B></FONT></P>
<P style="line-height:20px; margin:0px; padding-right:-24px; font-family:HelveticaNeueLT Std; font-size:17.333px" align=center><B>2008 FINANCIAL RESULTS</B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px"><B>HERCULES, CA &#150; February 26, 2009 &#150;</B> Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2008.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">Fourth-quarter reported revenues were $448.0 million, down 2.6% compared to $459.7 million reported for the fourth quarter of 2007. On a currency-neutral basis, quarterly revenues increased 3.0% compared to the same period last year. &nbsp;This increase was due primarily to organic growth across a wide range of products in Bio-Rad&#146;s two main areas, Life Science and Clinical Diagnostics. Fourth-quarter gross margin was 55.1% compared to 50.8% during the same quarter last year. This improvement was a result of product mix with a heavier emphasis on consumables as well as the elimination of some low margin products. The lower margin in the prior-year quarter reflected the impact of the DiaMed acquisition.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">The Company reported a net loss for the fourth quarter of $8.2 million compared to net income of $12.4 million during the fourth quarter last year. These results reflect non-cash impairment charges of $35.0 million, which include charges of $28.8 million for the impairment of goodwill and purchased intangibles and $6.2 million for impairment of investments. Additionally, income for the quarter was impacted by $5.2 million in foreign exchange loss due to significant currency fluctuations during the quarter. The extraordinarily high tax rate for the fourth quarter was due primarily to the nondeductible write-off of goodwill and the impairment of investments which did not result in a benefit for tax purposes. Fourth-quarter diluted loss per share from operations was $0.30 compared to diluted earnings of $0.45 per share during the same period last year.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">For the full year, sales grew by 20.8% to $1,764.4 million compared to $1,461.1 million in 2007. After normalizing for the impact of currency effects, Bio-Rad sales grew by 17.8%. Year-over-year net income was $89.5 million, or $3.25 per share on a diluted basis, compared to $93.0 million, or $3.41 per share, respectively, in 2007. Full-year gross margin was 54.6% compared to last year&#146;s figure of 54.2%. Margins were bolstered by better manufacturing efficiency coupled with a favorable product mix.</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px" align=center>(more)</P>
<P style="margin:0px"><BR>
<BR></P>
<P style="line-height:14.667px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:12px; page-break-before:always"><B><I>Bio-Rad Reports Fourth-Quarter and Full-Year 2008 Financial Results</I></B></P>
<P style="line-height:14.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Page 2</I></B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">&#147;We are pleased with the results of 2008. &nbsp;It was another successful year for Bio-Rad despite </P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">weakening of the capital equipment market. &nbsp;During the year we made progress on expanding our core business as well as integrating DiaMed into our organization,&#148; said Norman Schwartz, Bio-Rad President and Chief Executive Officer. &#147;We, like others, are approaching 2009 with caution. The economic environment could make growth for this year challenging; nevertheless, we expect it to be another year of laying the groundwork for long-term success.&#148;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px"><B>Life Science </B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">The Life Science segment net sales for the fourth quarter were $170.3 million, down 7.7% compared to the same period last year. On a currency-neutral basis, Life Science segment sales decreased by 3.0%. Full-year reported revenues for the Life Science segment were $643.5 million, up 4.6% over the prior year, or 1.4% on a currency-neutral basis. Growth in the Life Science segment was negatively impacted during the quarter by a drop in capital instrument sales, reflecting cutbacks by both academic and bio-pharmaceutical customers. Performance in the Life Science segment benefited from sales of the Company&#146;s protein separation and analysis tools including electrophoresis, chromatography, and imaging products. &nbsp;Segment performance was also boosted by sales of its Bio-Plex<SUP>&#174;</SUP> suspension array system reagents, as several new assay panels for the Bio-Plex system were introduced during the year. D
emand for the Company&#146;s next generation polymerase chain reaction (PCR) instruments continued to grow through the fourth quarter. During the fourth quarter, the segment introduced the CFX384 Real-Time PCR Detection System. &nbsp;This is a high-throughput version of the CFX product line introduced earlier in the year.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px"><B>Clinical Diagnostics</B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">The Clinical Diagnostics segment reported net sales of $274.0 million for the fourth quarter, up 0.9% compared to the prior-year quarter. &nbsp;Net sales were up 7.2% for the quarter on a currency-neutral basis. These results were due in good measure to continued growth across all product lines, most notably quality control, autoimmune, diabetes and blood virus testing. Placements of the Company&#8217;s BioPlex<SUP>&#174; &nbsp;</SUP>2200 system as well as sales of its rapid MRSA<I>Select</I><SUP>&#8482;</SUP> test also continued at a good pace. Full-year reported revenues for the Clinical Diagnostics segment were $1,106.4 million, a 33.0% increase compared to 2007 results principally due to the acquisition of DiaMed in the fourth quarter of 2007. Net of currency effects, revenues increased 30.1% compared to 2007 results.</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px" align=center>(more)</P>
<P style="line-height:21.333px; margin:0px" align=justify><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:12px; page-break-before:always" align=justify><B><I>Bio-Rad Reports Fourth-Quarter and Full-Year 2008 Financial Results</I></B></P>
<P style="line-height:14.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Page 3</I></B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:24.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px"><B>2008 Full-Year Highlights</B></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Full-year Company sales grew by 20.8% to $1,764.4 million. </FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Year-over-year net income was $89.5 million, down 3.7% compared to $93.0 million reported in 2007. &nbsp;This reduction was primarily due to non-cash impairments taken in the fourth quarter of 2008.</FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">During the first quarter, the Life Science group began shipping its next generation polymerase chain reaction (PCR) instruments, the new 1000-series thermal cycling and CFX Real Time platforms.</FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In January, the Clinical Diagnostics group announced the introduction to the U.S. market of Candi</FONT><I>Select&#8482;</I> &nbsp;4, a chromogenic medium used for the selective isolation of several forms of <I>Candida</I>, a genus of yeasts that can cause numerous infections in humans and animals. </P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In February, the Company announced the launch of the first and only fully-automated, random access multiplex test system for autoimmune systemic vasculitis testing. The BioPlex</FONT><SUP>&#174;</SUP> 2200 Vasculitis kit is for use on the BioPlex 2200 system, a platform that employs multiplexing technology to analyze multiple disease markers from a single patient sample.</P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In July, Bio-Rad announced FDA clearance for faster interpretation time of its existing MRSASelect&#8482; test, a chromogenic medium that is used for the rapid screening of MRSA (methicillin-resistant Staphylococcus aureus). With high sensitivity and specificity as well as rapid and direct identification, the MRSASelect test can now identify MRSA carriers in as little as 18 hours.</FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In September, the Clinical Diagnostics division launched the BioPlex</FONT><SUP>&#174;</SUP> 2200 Syphilis IgM kit in Europe. The new test detects IgM class antibodies to a bacterium that causes syphilis.</P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">In December, the Company purchased DiaMed GB Ltd, the exclusive distributor of DiaMed products in the United Kingdom (excluding Northern Ireland), and DiaMed Fennica Oy, the exclusive distributor of DiaMed products in Finland, Estonia, Latvia, and Lithuania. The total cash purchase price of these acquisitions was approximately $17 million. </FONT></P>
<P style="line-height:24px; margin-top:0px; margin-bottom:-24px; padding-left:48px; text-indent:-24px; font-family:Symbol"><FONT FACE="Symbol">&#183;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:48px; font-family:HelveticaNeueLT Std"><FONT FACE="HelveticaNeueLT Std">Also in December, Bio-Rad purchased certain assets of SafePath Laboratories, LLC&#146;s food diagnostics business. The terms of the purchase were not disclosed. With the purchase of SafePath&#146;s high performance serological immunoassay test kits for Trichinella, Toxoplasma and Salmonella pathogens, Bio-Rad expands its food diagnostics product line.</FONT></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) February 26, 2009. Interested parties may access the call by dialing 866-700-5192 (in the U.S.) or 617-213-8833 &nbsp;(international), access number 30538296. The live webcast can be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 82618947 for seven days following the call, and the webcast can be accessed at http://www.bio-rad.com for 30 days.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px" align=center>(more)</P>
<P style="line-height:21.333px; margin:0px" align=justify><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:12px; page-break-before:always" align=justify><B><I>Bio-Rad Reports Fourth-Quarter and Full-Year 2008 Financial Results</I></B></P>
<P style="line-height:14.667px; margin:0px; font-family:HelveticaNeueLT Std; font-size:12px"><B><I>Page 4</I></B></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px"><B>About Bio-Rad</B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:HelveticaNeueLT Std"><I>This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;continue,&#148; or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the &#147;Risk Factors&#148; in the Company&#146;s public reports filed with the Securities and Exchange Commission, including the Company&#146;s most recent Annual Report on Form 10-K, Quarterly Rep
orts on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. &nbsp;Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements. </I></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px"><B>For more information contact:</B></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">Ron Hutton, Treasurer</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">510-724-7000</P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">investor_relations@bio-rad.com<FONT FACE="Courier New"> </FONT></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=319.333></TD><TD width=74.533></TD><TD width=12></TD><TD width=71.667></TD><TD width=12></TD><TD width=77.667></TD><TD width=12.333></TD><TD width=71></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center><FONT FACE="Times New Roman">BIO-RAD LABORATORIES, INC.</FONT></P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Condensed Consolidated Statements of Income</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>(In thousands, except per share data)</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=158.2 colspan=3><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=161 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=158.2 colspan=3><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Three Months Ended</P>
<P style="line-height:14.667px; margin:0px; font-size:12px" align=center>December 31,</P>
</TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=161 colspan=3><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Twelve Months Ended</P>
<P style="line-height:14.667px; margin:0px; font-size:12px" align=center>December 31,</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2008</P>
</TD><TD style="border-top:1px solid #000000" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2007</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2008</P>
</TD><TD style="border-top:1px solid #000000" width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2007</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Net sales</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;447,965&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;459,688&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;1,764,365&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;1,461,052&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Cost of goods sold</P>
</TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>201,289&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>226,055&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>801,843&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>669,690&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Gross profit</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>246,676&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>233,633&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>962,522&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>791,362&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Selling, general and administrative expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>154,497&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>162,990&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>591,304&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>507,978&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Product research and development expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>41,120&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>39,855&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>159,518&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>140,535&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Purchased in-process research and development expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,656&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>--&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,656&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Impairment expenses</P>
</TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>28,757&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>--&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>28,757&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Income from operations</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>22,302&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>23,132&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>182,943&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>135,193&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Interest expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,985&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>8,023&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>32,113&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>31,606&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Foreign exchange losses, net</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>5,238&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>2,989&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,634&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>2,576&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Other (income) expense <B>, </B>net</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>5,020&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(464)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>353&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(19,832)</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Income before tax and minority interests</P>
</TD><TD style="border-top:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>4,059&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>12,584&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>142,843&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>120,843&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Provision (benefit) for income taxes</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>10,567&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(1,072)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>44,579&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,548&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Minority interests in earnings of consolidated subsidiaries</P>
</TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>1,708&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>1,301&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>8,754&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>1,301&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Net income (loss)</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;(8,216)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;12,355&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;89,510&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;92,994&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Basic earnings (loss) per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Net income (loss)</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;(0.30)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;0.46&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.32&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.49&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Weighted average common shares</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,142&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,780&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,001&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,684&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Diluted earnings (loss) per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Net income (loss)</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;(0.30)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;0.45&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.25&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.41&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Weighted average common shares</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,142&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,456&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,527&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,260&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; padding-left:-48px; padding-right:-65.333px; font-size:12px; page-break-before:always" align=center>BIO-RAD LABORATORIES, INC</P>
<P style="margin:0px; font-size:12px" align=center>Condensed Consolidated Balance Sheets</P>
<P style="margin:0px; font-size:12px" align=center>(In thousands)</P>
<P style="margin:0px; font-size:12px" align=center>(Unaudited)</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=415.667></TD><TD width=16.667></TD><TD width=91.4></TD><TD width=17></TD><TD width=90.467></TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="margin:0px; font-size:12px" align=center>December 31,</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="margin:0px; font-size:12px" align=center>December 31,</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=91.4><P style="margin:0px; font-size:12px" align=center>2008</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=90.467><P style="margin:0px; font-size:12px" align=center>2007</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Current assets: </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Cash and cash equivalents</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;204,524&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;161,764&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Short-term investments</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>38,950&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>61,977&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts receivable, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>339,653&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>358,076&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Inventories, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>375,616&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>321,015&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>135,198&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>126,142&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current assets </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>1,093,941&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>1,028,974&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Net property, plant and equipment </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>300,732&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>271,561&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Goodwill </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>321,820&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>328,439&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Purchased intangibles, net</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>228,590&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>210,304&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Other assets </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>92,181&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>132,316&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;2,037,264&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,971,594&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Current liabilities:</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Notes payable and current maturities of long-term debt</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9,578&nbsp;</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15,627&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts payable</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>117,982&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>96,470&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accrued payroll and employee benefits</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>119,420&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>121,255&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Sales, income and other taxes payable</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>33,731&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>27,905&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>137,323&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>152,911&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>418,034&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>414,168&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Long-term debt, net of current maturities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>445,979&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>441,805&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Other long-term liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>102,611&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>109,497&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Minority interests</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>29,909&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>34,434&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>1,040,731&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>971,690&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total liabilities, minority interests and stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;2,037,264&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,971,594&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="line-height:14.667px; margin-top:0px; margin-bottom:6px; font-size:12px">&nbsp;</P>
<P style="margin-top:0px; margin-bottom:6px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:6px; page-break-before:always"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=415.667></TD><TD width=84></TD><TD width=24></TD><TD width=84></TD></TR>
<TR><TD valign=top width=607.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=607.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Condensed Consolidated Statements of Cash Flows</P>
</TD></TR>
<TR><TD valign=top width=607.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=607.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(Unaudited) &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=192 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=192 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Year Ended</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=192 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>December 31,</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=84><P style="line-height:13.333px; margin:0px; font-size:12px" align=right>2008&nbsp;</P>
</TD><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=84><P style="line-height:13.333px; margin:0px; font-size:12px" align=right>2007&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from operating activities:</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash received from customers</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;1,765,667&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;1,467,626&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash paid to suppliers and employees</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,495,669)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,225,968)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Interest paid</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(30,792)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(30,588)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Income tax payments</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(49,159)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(38,253)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Litigation settlement </P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(4,493)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(4,228)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other operating activities</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>5,817&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>22,991&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash provided by operating activities</P>
</TD><TD style="border-top:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>191,371&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>191,580&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from investing activities:</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Payment for acquisitions, net of cash received, and long-term investments</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(53,014)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(387,673)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other investing activities</P>
</TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(93,093)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>133,244&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash used in investing activities</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(146,107)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(254,429)</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from financing activities:</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Payments on long-term debt</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(11,589)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(17,720)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Other financing activities</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>17,920&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>10,270&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Net cash provided by (used in) financing activities</P>
</TD><TD style="border-top:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>6,331&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(7,450)</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Effect of exchange rate changes on cash</P>
</TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(8,835)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>8,456&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net increase (decrease) in cash and cash equivalents</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>42,760&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(61,843)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at beginning of period</P>
</TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>161,764&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>223,607&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at end of period</P>
</TD><TD style="border-bottom:2.667px double #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;204,524&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;161,764&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin:0px; font-size:12px">Reconciliation of net income to net cash provided by operating activities:</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin:0px; font-size:12px">Net income </P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;89,510&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;92,994&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Adjustments to reconcile net income to net cash provided by&nbsp;</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:9.6px; font-size:12px">operating activities (net of effects of acquisitions):</P>
</TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Depreciation and amortization</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>97,088&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>67,258&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Impairment expense</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>28,757&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Changes in working capital</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(46,563)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>11,038&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Litigation settlement</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(4,493)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(4,228)</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Other</P>
</TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>27,072&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>24,518&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net cash provided by operating activities</P>
</TD><TD style="border-top:1px solid #000000; border-bottom:2.667px double #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;191,371&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-bottom:2.667px double #000000" width=84><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;191,580&nbsp;</P>
</TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=84><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=right><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
